<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Innovations

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Default sub title

minute read

by PR Newswire | October 23, 2025
placeholder

Topics: Press Coverage

Related Articles

Partners

Children's Hospital of Colorado Center for Innovation

Colorado Clinical and Translational Sciences Institute

Fitzsimons Innovation Community

UCHealth Innovation Center

© 2025  The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.